Audience: Patients and the public. Published 16 November 2026 (AEDT).
Australia’s medicines regulator, the Therapeutic Goods Administration (TGA), has registered a once-daily tablet form of Wegovy (semaglutide), with four strengths added to the Australian Register of Therapeutic Goods on 3 November 2026. It is the first GLP-1 medicine approved in Australia as a tablet for weight management. Until now, Wegovy has only been available here as a weekly injection.
Who is it approved for?
The tablet is a prescription medicine for adults with a body mass index (BMI) of 30 or more, or 27 or more with at least one weight-related health condition, used alongside a reduced-energy diet and more physical activity. It is also approved to lower the risk of heart attack, stroke and cardiovascular death in adults with established heart or blood vessel disease and a BMI of 27 or more who do not have diabetes. Unlike the injection, the tablet is not approved for teenagers.
What did the main trial show?
The key study (OASIS 4) randomly assigned 307 adults without diabetes to the 25 mg tablet or a dummy tablet for 64 weeks, with diet and exercise advice for everyone. People taking the tablet lost an average of 13.6% of their body weight, compared with 2.2% on the dummy tablet. That is roughly 14 kg versus 2 kg on average. About 47 in 100 people on the tablet lost at least 15% of their weight, compared with about 5 in 100 on the dummy tablet. Results vary a lot between individuals.
Side effects were common. Stomach and bowel symptoms such as nausea, diarrhoea, vomiting and constipation were reported by 74% of people on the tablet and 42% on the dummy tablet, mostly while the dose was being increased. The heart-protection evidence comes from a large trial of the weekly injection, not the tablet itself.
How it is taken
The tablet must be swallowed whole each morning on an empty stomach with no more than half a glass of water, then you wait at least 30 minutes before eating, drinking or taking other tablets. The dose starts low and is increased monthly. It should not be combined with other GLP-1 medicines, and it should not be used in pregnancy.
Availability and cost
Approval does not mean it is in pharmacies yet. The manufacturer has said it expects the tablet to be available later in 2026. Wegovy is not subsidised on the PBS for weight management, so people should expect to pay the full private price.
Limitations
The trial was funded by the manufacturer, involved mostly White participants, and ran for just over a year, so long-term results and effects in more diverse groups are less certain. Weight often returns when GLP-1 medicines are stopped. This article draws on the official product information and the trial summary; the full journal article was not reviewed.
If you are interested in this medicine, talk to your regular GP, who can consider your history, other medicines and whether it suits you.
Prepared with AI assistance from the linked sources; not individually reviewed by a clinician. General information only, not individual medical advice.
Sources
TGA: Australian Product Information for Wegovy (semaglutide), AusPAR attachment dated 11 November 2026 (accessed 16 November 2026, AEDT).
Wharton S, et al. Oral semaglutide at a dose of 25 mg in adults with overweight or obesity (OASIS 4). N Engl J Med 2025;393:1077–87 (PubMed abstract) (accessed 16 November 2026, AEDT).
RACGP newsGP: TGA approves Wegovy weight-loss pill, 4 November 2026 (accessed 16 November 2026, AEDT).
ABC News: How the Wegovy pill compares to weight-loss injections, 5 November 2026 (accessed 16 November 2026, AEDT).